US Edition
News from Yadkin Ripple
We’ve assigned a media bias rating of Lean Left to Yadkin Ripple. You can read more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Lean Left
Lean Left
byMedia Bias/Fact CheckDo you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Yadkin Ripple News
West Virginia · West Virginia(BPT) - For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that one in three will see their cancer return…See the Story
New clinical trial aims to prevent relapse in patients with DLBCL
77% Center coverage: 79 sources
Western Australia · Western AustraliaTORONTO and PERTH, Australia, June 22, 2025 /PRNewswire/ - Kinterra Capital GP Corp. II ("Kinterra"), in its capacity as general partner of the Kinterra Critical Materials & Infrastructure Opportunities Fund II, LP, confirms that it has submitted a non-binding, indicative…See the Story
Kinterra Capital Submits Proposal to Acquire 100% of New World Resources
57% Center coverage: 35 sources
Risen Energy Highlights Advancements in Green Manufacturing, Sustainable Development and Corporate Responsibility in 2024 ESG Report
58% Center coverage: 34 sources
Lawmakers aren’t deadlocked on regulation
100% Left coverage: 2 sources
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
62% Center coverage: 29 sources
EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds
66% Center coverage: 29 sources
Breakthrough: Roche's New Hemophilia Drug Achieves Zero Bleeds in Clinical Trial, Challenges Market Leader
66% Center coverage: 24 sources
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
70% Center coverage: 26 sources
